Analytical Data
-
Gene name
Claudin-6/CLDN6
- Application
-
Alternative Names
Claudin-6; Skullin; CLDN6; Claudin6; Skullin 2
-
Species
Human
-
Source
HEK293
-
Tag
Tag Free
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P56747
-
Expression Region
M1-V220
-
Protein Length
Full Length
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Claudin-6 (CLDN6) is a member of the claudin family of proteins, which play crucial roles in the formation and maintenance of tight junctions between epithelial cells. These tight junctions are essential for regulating paracellular permeability and maintaining tissue integrity. Research has shown that CLDN6 is highly expressed in certain cancers, including germ cell tumors and various carcinomas, making it a potential biomarker and therapeutic target. The recombinant expression of CLDN6 has enabled scientists to study its structural and functional properties in detail. Previous studies suggest that CLDN6 might also be involved in signaling pathways that govern cell proliferation and differentiation. Additionally, its unique expression pattern in certain malignancies provides opportunities for targeted therapies, such as monoclonal antibodies or CAR-T cell approaches. The development of CLDN6 recombinant proteins has advanced our understanding of its role in cancer biology and tight junction dynamics and offers promising avenues for diagnostic and therapeutic strategies in oncology. Through the generation of CLDN6 fusion proteins, researchers aim to elucidate its mechanisms of action and explore its potential as a target for clinical interventions in cancer treatment.
